CT017
/ CARsgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 09, 2023
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial.
(PubMed, EClinicalMedicine)
- P1 | "CT017 CAR T cells were engineered to co-express CAR-GPC3 and runt-related transcription factor 3 (RUNX3), which triggers CD8 T-cell infiltration into the cancer microenvironment...These results need to be confirmed in a robust clinical trial. This study was funded by CARsgen Therapeutics Co., Ltd."
CAR T-Cell Therapy • Journal • Metastases • P1 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • GPC3 • RUNX3 • TCF3
1 to 1
Of
1
Go to page
1